(Q38108574)

29 August 2017

title

Publication bias, with a focus on psychiatry: causes and solutions (English)

1 reference

29 August 2017

0 references

1 reference

Erick H Turner

1

0 references

publication date

1 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

457-468

1 reference

The existence of publication bias and risk factors for its occurrence

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The file drawer problem and tolerance for null results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Bias, spin, and misreporting: time for full access to trial protocols and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Time-lag bias in trials of pediatric antidepressants: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Publication bias: evidence of delayed publication in a cohort study of clinical research projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A case study of salami slicing: pooled analyses of duloxetine for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Different patterns of duplicate publication: an analysis of articles used in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

"Place of publication" bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Citation bias favoring statistically significant studies was present in medical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Citation bias in reported smoking prevalence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Better reporting of harms in randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Negative results are disappearing from most disciplines and countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reboxetine in depression. All the relevant data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Publication bias and outcome reporting bias: agomelatine as a case example

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The failure to know what isn't known: negative publication bias with lamotrigine and a glimpse inside peer review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The Neurontin legacy--marketing through misinformation and manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Narrative review: the promotion of gabapentin: an analysis of internal industry documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reporting bias in medical research - a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Replication studies: Bad copy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Key opinion leaders: independent experts or drug representatives in disguise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Confidentiality agreements and scientific independence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Investigator experiences with financial conflicts of interest in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Design and reporting modifications in industry-sponsored comparative psychopharmacology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Retrospective cohort study highlighted outcome reporting bias in UK publicly funded trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Do pressures to publish increase scientists' bias? An empirical support from US States Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Hindsight Bias: On Being Wise After the Event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

HARKing: hypothesizing after the results are known

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Biases in medication prescribing: the case of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Underreporting research is scientific misconduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The refiguration of medical thought

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Perceived information gain from randomized trials correlates with publication in high-impact factor journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A reviewer's perspective on multiple endpoint issues in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Testing multiple statistical hypotheses resulted in spurious associations: a study of astrological signs and health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The Hamilton Depression Rating Scale: has the gold standard become a lead weight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A Structured Interview Guide for the Hamilton Depression Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

False-Positive Psychology: Undisclosed Flexibility in Data Collection and Analysis Allows Presenting Anything as Significant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Definition and epidemiology of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Unreported cholesterol drug data released by company

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Correction/clarification about FDA review documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A taxpayer-funded clinical trials registry and results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The ClinicalTrials.gov results database--update and key issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Trial Registration at ClinicalTrials.gov between May and October 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Failing the public health--rofecoxib, Merck, and the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The evolution of trial registries and their use to assess the clinical trial enterprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The quality of registration of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Medicine. Moving toward transparency of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Reporting "basic results" in ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Modulation of ligand-gated ion channels as a novel pharmacological principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Study design features affecting outcome in antidepressant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Opening up data at the European Medicines Agency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Open clinical trial data for all? A view from regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Access to regulatory data from the European Medicines Agency: the times they are a-changing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Publication bias: what are the challenges and can they be overcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Editorial policies and publication bias: the importance of negative studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Outcome-blinded peer review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The need for publishing the silent evidence from negative trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Why most published research findings are false

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Use of trial register information during the peer review process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

Magnitude of effects in clinical trials published in high-impact general medical journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0067-9

NIH clinical trials and publication bias

21 January 2018

1 reference

12 December 2020

Misunderstanding publication bias: editors are not blameless after all.

1 reference

12 December 2020

Roche says it will not relinquish control over access to clinical trial data.

1 reference

12 December 2020

The Hamilton depression scale. Evaluation of objectivity using logistic models

1 reference

12 December 2020

Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression

1 reference

12 December 2020

Relationship between baseline severity of depression and antidepressant treatment outcome

1 reference

12 December 2020

Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder

1 reference

12 December 2020

Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study

1 reference

12 December 2020

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

12 December 2020

Assessing full remission.

1 reference

12 December 2020

Citation bias: supporting your case in the extreme.

1 reference

12 December 2020

Closing a loophole in the FDA Amendments Act

1 reference

12 December 2020

Sensitivity of the six-item Hamilton Depression Rating Scale

1 reference

12 December 2020

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study

1 reference

12 December 2020

Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

1 reference

12 December 2020

Prose and principle: getting your message across: more than detailed cataloguing of research findings, emphasis of principles within a narrative engages the readers of reviews

1 reference

12 December 2020

Transparency at the Food and Drug Administration

1 reference

12 December 2020

10.1007/S40263-013-0067-9

Identifiers

DOI

1 reference

29 August 2017

1 reference